Search company, investor...

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$273.6M

Valuation

$0000 

Revenue

$0000 

About Relievant Medsystems

Relievant Medsystems operates a commercial-stage medical device company. It offers various diagnoses and treatments of vertebrogenic pain with the intracept system, a minimally invasive procedure delivering targeted energy into the spine and blocking the transmission of pain signals from the basivertebral nerve. The company was founded in 2006 and is based in Edina, Minnesota. In September 2023, Relievant Medsystems was acquired by Boston Scientific. Per Boston Scientific, there were also "undisclosed additional contingent payments based on sales performance over the next three years. On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges."

Headquarters Location

7201 Metro Boulevard Suite 300

Edina, Minnesota, 55439,

United States

650-368-1000

Loading...

Loading...

Relievant Medsystems Patents

Relievant Medsystems has filed 67 patents.

The 3 most popular patent topics include:

  • bones of the vertebral column
  • neurosurgery
  • orthopedic surgical procedures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/13/2020

8/29/2023

Bones of the vertebral column, Orthopedic surgical procedures, Neurosurgery, Manual therapy, Musculoskeletal disorders

Grant

Application Date

3/13/2020

Grant Date

8/29/2023

Title

Related Topics

Bones of the vertebral column, Orthopedic surgical procedures, Neurosurgery, Manual therapy, Musculoskeletal disorders

Status

Grant

Latest Relievant Medsystems News

Dave Amerson and Tyler Binney Add Their Experience Commercializing Disruptive Technologies to Intrinsic Therapeutics' Board of Directors

Feb 13, 2024

News provided by Share this article Share toX WOBURN, Mass., Feb. 13, 2024 /PRNewswire/ -- Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA approved medical device proven to significantly reduce reherniations and reoperations following lumbar discectomy surgery, today announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors. "We are thrilled to welcome these two highly regarded industry leaders to our board," said Cary Hagan, President and CEO. "Dave and Tyler bring a wealth of experience in launching disruptive technologies and developing high-growth companies and will provide invaluable guidance as we aggressively expand our sales activities this year. With these board additions, Intrinsic is well-positioned to rapidly increase patient access to Barricaid." Dave Amerson served as President and CEO of NeoTract, Inc. until its acquisition by Teleflex in 2017 for $1.1 billion. Dave previously served as Chairman of the Board at Palette Life Sciences until its acquisition by Teleflex for $600 million in 2023 and was a Board Member of Relievant Medsystems, Inc. until its acquisition for by Boston Scientific in 2023. He currently serves on the board of directors of Calyxo, Moximed, Revelle and the Urology Care Foundation. He holds an M.B.A. from Argosy University and a B.A. in Political Science from the University of West Georgia. Tyler Binney is currently President and CEO of Relievant Medsystems, which was recently acquired by Boston Scientific for $850 million plus a performance-based earnout. Prior to joining Relievant, Tyler served as President and General Manager of Interventional Urology at Teleflex, and as Vice President of Sales for NeoTract. Prior to NeoTract, Tyler served in multiple leadership roles in sales and marketing at Johnson & Johnson. Tyler holds a Bachelor of Science in Biology from Presbyterian College. Ryan Drant, the Chairman of Intrinsic's Board of Directors added, "I am thrilled to welcome Dave and Tyler to the Intrinsic board and I am confident they will help drive rapid growth and add huge value to the company. I worked closely with both Dave and Tyler during my time as a board member at NeoTract so I have firsthand knowledge of their amazing talent for driving commercial growth." About Barricaid Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in more than eleven thousand patients and is supported by clinical studies in eight distinct patient populations, including two randomized controlled trials and six single armed trials. A multicenter level I RCT demonstrating superior outcomes to discectomy alone with 5-year results was published in JAMA. Recently, the Centers for Disease Control issued ICD-10 codes to track and monitor defect size in discectomy patients, confirming medical necessity for Barricaid. For full benefit-risk information, please visit www.Barricaid.com Media Contact: 760-525-9739

Relievant Medsystems Frequently Asked Questions (FAQ)

  • When was Relievant Medsystems founded?

    Relievant Medsystems was founded in 2006.

  • Where is Relievant Medsystems's headquarters?

    Relievant Medsystems's headquarters is located at 7201 Metro Boulevard, Edina.

  • What is Relievant Medsystems's latest funding round?

    Relievant Medsystems's latest funding round is Acquired.

  • How much did Relievant Medsystems raise?

    Relievant Medsystems raised a total of $273.6M.

  • Who are the investors of Relievant Medsystems?

    Investors of Relievant Medsystems include Boston Scientific, Canaan Partners, New Enterprise Associates, Morgenthaler Ventures, Endeavour Vision and 9 more.

  • Who are Relievant Medsystems's competitors?

    Competitors of Relievant Medsystems include BioWave, Autonomic Technologies, SteadyMed Therapeutics, Belmont Instrument, Spinal Modulation and 7 more.

Loading...

Compare Relievant Medsystems to Competitors

T
Trigemina

Trigemina focuses on developing innovative therapies in the pharmaceutical industry, specifically targeting chronic migraine and neuropathic pain without the use of opioids. The company's main offerings include non-sedating, cognition neutral neurological therapies that leverage novel naso-cerebral delivery systems to provide relief. It is based in Moraga, California.

A
AllTranz

AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.

BioWave Logo
BioWave

BioWave is a company that focuses on the development of non-opioid, patented pain blocking technology in the healthcare industry. The company's main offerings include wearable devices that deliver high-frequency neurostimulation to pain nerves, inhibiting the propagation of action potential along the nerve and blocking the transmission of pain signals to the brain. This technology is primarily used in the sports medicine and chronic pain management sectors. It was founded in 1997 and is based in Norwalk, Connecticut.

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops implantable bioelectronic therapies to treat chronic inflammatory diseases.. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. It was formerly known as Innovative Metabolics. The company was founded in 2007 and is based in Valencia, California.

S
SpineAlign Medical

SpineAlign Medical is an early-stage medical device company focused on developing minimally-invasive products for spine disorders. The company's main product is a nitinol implant designed to treat vertebral compression fractures, primarily affecting osteoporosis patients. SpineAlign Medical's technologies cater to the healthcare sector, with a focus on improving patient outcomes in spinal treatments. It is based in Pleasanton, California.

S
Salutaris Medical Devices

Salutaris Medical Devices is a clinical stage medical device company focused on the ophthalmic sector. The company's main product is a patented, FDA-cleared device called BetaCurve, designed to treat various eye diseases, including advanced age-related macular degeneration, using precision beta radiotherapy. The device is used in a quick, outpatient procedure that requires only one treatment, offering a potential alternative for patients who do not respond well to standard treatments. It is based in Tucson, Arizona.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.